- Home
- SABA vs CRBP Comparison
SABA vs CRBP Comparison
Compare SABA & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SABA | CRBP |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.6M | 134.8M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SABA | CRBP |
|---|---|---|
| Price | $8.14 | $10.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.83 |
| AVG Volume (30 Days) | 117.3K | ★ 173.4K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $99.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $7.72 | $4.64 |
| 52 Week High | $9.46 | $20.56 |
Technical Indicators
Market Signals| Indicator | SABA | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 72.42 |
| Support Level | $7.97 | $9.08 |
| Resistance Level | $8.27 | $11.64 |
| Average True Range (ATR) | 0.10 | 0.58 |
| MACD | 0.02 | 0.29 |
| Stochastic Oscillator | 54.31 | 98.08 |
Price Performance
Historical ComparisonAbout SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.